Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-18-053536
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-02 21:38:44
Reporting Period:
2018-09-28
Accepted Time:
2018-10-02 21:38:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1724344 Entasis Therapeutics Holdings Inc. ETTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1252522 Nicholas Galakatos C/o Entasis Therapeutics Holdings Inc.
35 Gatehouse Drive
Waltham MA 02451
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-09-28 361,829 $0.00 361,829 No 4 C Indirect See Footnote
Common Stock Acquisiton 2018-09-28 323,341 $0.00 685,170 No 4 C Indirect See Footnote
Common Stock Acquisiton 2018-09-28 412,583 $0.00 1,170,010 No 4 C Indirect See Footnote
Common Stock Acquisiton 2018-09-28 453,395 $15.00 1,623,405 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Convertible Preferred Stock Disposition 2018-09-28 7,500,000 $0.00 361,829 $0.00
Common Stock Series B-1 Tranche A Convertible Preferred Stock Disposition 2018-09-28 6,702,213 $0.00 323,341 $0.00
Common Stock Series B-1 Tranche B Convertible Preferred Stock Disposition 2018-09-28 8,552,024 $0.00 412,583 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
  2. The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. The Reporting Person, a director of the Issuer, is a managing director of Clarus III GP LLC. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
  3. This number includes an aggregate of 72,257 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.